ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

The New NCI: Structure, Procedures, Advisory Boards To Change, Klausner Says

September 15, 1995

Two Children Achieve Remission With CD19 Immunotherapy

March 29, 2013

FASEB Urges 6.7 Percent Increase In NIH Budget.

February 1, 2008

Studies Link Age-Dependent Outcome To Immune Cells

November 28, 2003

Virus Cancer Program Report On Scientific Activities

August 1, 1975

In Brief: NIH Call For Review Group Nominations Brings 8,000 Names For 400 Vacancies

August 17, 1979